Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
|Brain: Rostral Ventromedial Medulla|
|RVM is labeled 5 in red at the bottom|
The rostral ventromedial medulla (RVM), is a group of neurons located close to the midline on the floor of the medulla (myelencephalon). The rostral ventromedial medulla sends descending inhibitory and excitatory fibers to the dorsal horn spinal cord neurons.
There are 3 categories of neurons in the RVM. On-cells, off-cells, and neutral cells. They are characterized by their response to nociceptive input. Off-cells show a transitory decrease in firing rate right before a nociceptive reflex, and are theorized to be inhibitory. Activation of off-cells, either by morphine or any other means, results in antinociception. On-cells show a burst of activity immediately preceding nociceptive input, and are theorized to be contributing to the excitatory drive. Neutral cells show no response to nociceptive input.
Involvement in Neuropathic pain
Research has shown the RVM to be important in the maintenance of neuropathic pain. Ablation of μ-opioid expressing neurons in the RVM with a dermorphin-saporin conjugate eliminated the allodynia and hyperalgesia caused by a nerve injury. Treatment with the dermorphin-saporin conjugate did not alter baseline pain thresholds, or affect sensitivity in the first 5–10 days after nerve injury. This suggests that the RVM contributes to the persistent pathology caused by nerve injury.
Further research determined that a large majority of μ-opioid expressing neurons also expressed CCK2 receptors. Microinjection in the RVM with either a CCK-saporin or dermorphin-saporin conjugate eliminated neurons expressing either receptor. Injection of the CCK-saporin conjugate also reversed allodynia and hyperalgesia in a nerve injury model, producing the same results as the dermorphin-saporin conjugate. This destruction of neurons was relatively specific, as less than 10% of neurons in the RVM were destroyed. This suggests that the targeted neurons are the ones responsible for maintaining chronic neuropathic pain states, and that the observed effect wasn't due to diffuse destruction of RVM neurons.
To help determine whether the persistent pain state was centrally or peripherally mediated, non-noxious stimuli were applied to the nerve injured limb. In animals receiving vehicle injections into the RVM, there was an increase in FOS expression in the superficial and deep dorsal horn of the spinal cord, indicating activation of nociceptive neurons. Animals receiving the dermorphin-saporin conjugate into the RVM had significantly less FOS expression. This indicates that a persistent neuropathic pain state is centrally mediated.
Role of Serotonin in Pain Modulation
Serotonin receptors have been hypothesized to play a bidirectional role in the modulation of pain. Based on previous experiments, a 5-HT3 antagonist, ondansetron, and a 5-HT7 antagonist, SB-269,970, were chosen to study.
System or intra-RVM injections of morphine produced dose-dependent antinociception. Spinal administration of SB-269970 reduced morphine-induced antinociception, whereas spinal administration of ondansetron had no effects. SB-269970 and ondansetron were then tested for their efficacy in reducing nociceptive responses. Allodynia and hyperalgesia were experimentally induced by administration of CCK into the RVM. Spinal administration of SB-269970 had no effect on nociception, whereas ondansetron completely reversed the effects of CCK injection. Spinal ondansetron also reversed allodynia and hyperalgesia caused by a peripheral nerve injury. Taken together, these findings indicate a role for 5-HT7 receptors in opioid induced antinociception, and a role for 5-HT3 in pro-nociceptive facilitation.
One limiting factor is that SB-269970 was also found to be a potent α2-adrenergic antagonist. Since the study using SB-269970 did not use a α2-adrenergic antagonist as a control, it is possible that some of the effects of SB-269970 are from its adrenergic effects.
Effects of Substance P and Neurokinin 1 receptors
The RVM contains high levels of both the neurokinin 1 receptor and its endogenous ligand, Substance P (SP). Microinjections of SP into the RVM resulted in transient antinociception to noxious heat stimuli, but not mechanical stimuli. Pretreatment with a neurokinin 1 (NK1) antagonist prevented the antinociception induced by SP injection, but the NK1 antagonist had no effects on pain threshold by itself. To test the effects of an NK1 antagonist during injury states, an NK1 antagonist was microinjected into the RVM after application of Freund's Complete Adjuvant (CFA), a chemical used for inflammation models. Administration of the NK1 antagonist reversed the heat hyperalgesia caused by CFA. In contrast, the administration of an NK1 antagonist further increased the tactile hyperalgesia induced by CFA. However, the NK1 antagonist did prevent some tactile hyperalgesia induced by a different compound, capsaicin. In yet another induced injury model using mustard oil (a TRPA1 agonist), NK1 antagonists did not affect thermal or tactile hyperalgesia.
In contrast to the study above, another group of researchers found that microinjection of SP into the RVM resulted in transient thermal hyperalgesia, which persisted long-term when continuous infusion pumps were implanted. To look more at the SP-NK1 signaling, they performed Western Blots of RVM slices, looking for NK1 receptor expression. NK1 receptor expression was increased from 2 hours to 3 days after administration of CFA.
NK1 agonism induced hypersensitivity is dependent on 5-HT3 receptors, and modulated by GABAA and NMDA receptors as well. Animals were pretreated with spinally administered Y-25130 or ondansetron, both 5-HT3 antagonists, before having RVM injections of SP. Both Y-25130 and ondansetron inhibited SP induced thermal hyperalgesia. GABAA receptor involvement was demonstrated by intrathecal administration of gabazine, a GABAA antagonist, in animals receiving continuous infusions of SP into the RVM. Gabazine treatment completely reversed the thermal hyperalgesia. The mechanism behind GABA involvement was investigated using ""in vitro"" recordings from animals treated with continuous infusions of SP or saline into the RVM. In SP treated neurons, GABA evoked depolarization, while in saline treated neurons it caused hyperpolarization. "These results suggest that descending facilitation induced by RVM SP administration produces GABAA receptor-evoked depolarization and an increase in excitation of dorsal horn neurons." Next, a GABA A agonist, muscimol was tested in conjuncture with SP. Intrathecal muscimol significantly enhanced SP-induced hypersensitivity, which was blocked by intrathecal gabazine. Next the researchers looked at threonine phosphorylation of NKCC1 proteins, which are an isoform of the Na-K-Cl cotransporter. Phosphorylation of these proteins results in increase activity of the cotransporter. Chronic administration of RVM SP or acute SP combined with intrathecal muscimol resulted in significantly higher levels of phosphorylated NKCC1.
Involvement of NMDA receptors
The role of NMDA receptors in non-inflammatory noxious stimuli was examined. The injury model consisted on two injections of acidic saline (pH = 4.0), and was designed to model non-inflammatory muscular pain. Intra-RVM administration of AP5 or MK-801, NMDA receptor antagonists, resulted in a reversal of the mechanical sensitivity induced by the acidic saline.
Behavioral hyperalgesia in inflammatory pain states is closely correlated with phosphorylation of spinal NMDA receptors. To find out more about the role of NMDA receptors in RVM pain facilitation, intrathecal MK-801 was administered before a RVM SP injection. Pretreatment with MK-801 significantly reduced SP induced hyperalgesia. Intrathecal MK-801 also blocked hyperalgesia resulting from continuous SP infusions. SP also increased the phosphorylation of the NR1 subunit of NMDA receptors.
In order to find out the relationship between GABA, NMDA, and SP, MK-801 was administered intrathecally to determine the effect on muscimol potentiation of SP hyperalgesia. MK-801 reduced the exaggeration of SP hyperalgesia induced by muscimol. Also, low doses of SP and intrathecal muscimol increased the expression of phosphorylated NR1 subunits of NMDA receptors. Intrathecal gabazine treatment before muscimol blocked the increase in phosphorylated NR1 expression.
On and off cells were both activated by local administration of ATP, a P1 and P2 agonist, whereas neutral cells were inhibited. However, on-cells and off-cells differed in their response to P2X and P2Y agonists.
On cells displayed a greater response to P2X agonists vs P2Y agonists. For example, α,β-methylene ATP, a P2X agonist, activated all on cells, whereas 2-methylthio-ATP, a P2Y agonist, only activated 60% of on cells tested. All on cells showed a response to a non-specific P2 agonist, uridine triphosphate (UTP). Activation of on cells by ATP was reversed by using the P2 antagonists suramin and pyridoxal-phosphate-6-azophenyl-2′,4′disulphonic acid (PPADS), but not with the P2Y antagonist MRS2179.
In contrast, off-cells were more responsive to P2Y agonists. 2-methylthio-ATP activated all off-cells, whereas α,β-methylene ATP, a P2X agonist, only activated one-third of off-cells. Off-cells were also activated by UTP, but lacked any response to adenosine, a P1 agonist. Activation of off-cells by ATP was inhibited by suramin, PPADS, and MRS2179.
Histological staining by another research group examined the distribution of purinergic receptor subtypes throughout the RVM. P1, P2X1, and P2X3 all showed moderate labeling density, with slightly greater densities observed in the nucleus raphe magnus and the raphe pallidus. In contrast, P2Y1 showed lower levels of labeling. P1 and P2Y1 were shown to be co-localized, as well as P2X1 and P2Y1. Presence of the raphe nuclei in the RVM also led to staining for tryptophan hydroxylase (TPH), a marker for serotonin (5-HT) positive neurons, and looking for co-localization of 5-HT neurons with purinergic receptors. Only about 10% of RVM neurons were TPH positive, but of those labeled for TPH, a large majority were co-labeled with purinergic antibodies. 55% of TPH+ neurons stained for P1, 63% for P2X1, 64% for P2X3, and 70% P2Y1.
- ↑ 1.0 1.1 1.2 Urban, M.O. (July 1999). Supraspinal contributions to hyperalgesia. PNAS 96 (14): 7687–7692.
- ↑ Morgan, Michael (November 2008). Periaqueductal Gray neurons project to spinally projecting GABAergic neurons in the rostral ventromedial medulla. Pain 140 (2): 376–386.
- ↑ 3.0 3.1 3.2 (July 2006). Descending facilitation from the rostral ventromedial medulla maintains nerve injury-induced central sensitization. Neuroscience 140 (4): 1311–20.
- ↑ Zhang, Wenjun (March 2009). Neuropathic pain is maintained by brainstem neurons co-expressing opioid and cholecystokinin receptors. Brain 132 (3): 778–787.
- ↑ 5.0 5.1 Dogrul, Ahmet (July 2009). Differential mediation of descending pain facilitation and inhibition by spinal 5HT-3 and 5HT-7 receptors. Brain Research 1280: 52–59.
- ↑ Hamity, Marta V. (February 2010). Effects of Neurokinin-1 Receptor Agonism and Antagonism in the Rostral Ventromedial Medulla of Rats with Acute or Persistent Inflammatory Nociception. Neuroscience 165 (3): 902–913.
- ↑ 7.0 7.1 7.2 7.3 7.4 Lagraize, S.C. (December 2010). SPINAL CORD MECHANISMS MEDIATING BEHAVIORAL HYPERALGESIA INDUCED BY NEUROKININ-1 TACHYKININ RECEPTOR ACTIVATION IN THE ROSTRAL VENTROMEDIAL MEDULLA. Neuroscience 171 (4): 1341–1356.
- ↑ Silva, LFS (April 2010). Activation of NMDA receptors in the brainstem, rostral ventromedial medulla, and nucleus reticularis gigantocellularis mediates mechanical hyperalgesia produced by repeated intramuscular injections of acidic saline in rats.. J Pain 11 (4).
- ↑ 9.0 9.1 9.2 9.3 Selden, N.R. (June 2007). Purinergic actions on neurons that modulate nociception in the rostral ventromedial medulla. Neuroscience 146 (4): 1808–1816.
- ↑ Close, L.N. (January 2009). Purinergic Receptor Immunoreactivity in the Rostral Ventromedial Medulla. Neuroscience 158 (2): 915–921.
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|